Sistemic Launch SistemTOX™ (v1) First microRNA-Based Toxicity Screening Service
Unveiling of new service is set to significantly reduce cost of drug development
Glasgow, Scotland, November 15th, 2010 – Sistemic Ltd., the recent winners of the coveted Most Promising Life Science Company by Nexxus, today announced the launch of their SistemTOX™ early predictive and investigative drug toxicity screening service. SistemTOX™ is aimed at reducing R&D costs and consequently accelerating drug development by filtering out unfit compounds early in the development process, presenting much needed cost savings to drug developers.
The launch of SistemTOX™ comes at a time when the industry has been experiencing huge issues with compound toxicity. Sistemic CEO Professor Chris Hillier stated “The strength of Sistemic’s approach will be in the intelligent use of microRNA profiling to decipher, early on, potential toxicity. Studies have shown that the SistemTOX™ approach can highlight potential toxicity at an early stage and allow assessment of critical pathways which could lead to toxicity in later clinical use. This service is applicable to cell lines such as HepG2 but also to stem cell derived hepatocytes and cardiomyocytes for example. It is not just a yes/no answer, it also provides context which feeds important information quickly back to the scientists. Basically it places the power back into the developer’s hands and reduces risk.” SistemTOX™ has been extensively evaluated with selected partners and Sistemic welcome interest from companies who wish to get a better and faster understanding of potential toxicity, as early in the lead development process as possible. Linked to the extensive suite of Sistemic drug development products (SistemKB™, SistemRNA™, SistemKB™ and SistemBM™) SistemTOX™ adds another key component to help companies achieve faster, more effective and therefore less costly drug development.
About SistemRNA™ - SistemRNA™ is the enabling platform which flows through our services and kits. SistemRNA™ analysis captures the microRNA dynamic response of all the cellular pathways in response to a stimulus, as well as their interactions, giving enhanced clarity without data overload. This simplistic yet highly informative approach delivers robust fundamental biological understanding enabling key decision making throughout the research and manufacturing process.
About Sistemic Ltd – Sistemic’s primary business is focused on providing innovative microRNA-based problem solving services and kit based products to areas of unmet need within Pharmaceutical, Biotechnology markets and the Bioprocessing community.
On the 24th March 2020 we let everyone know that in order to comply with the UK and Scottish Governments' lock down restrictions, the company would temporarily close at the end of the working day 24th March 2020.
We have now put the necessary IT infrastructure to allow all staff to work from home, and also the social distancing measures to allow lab work to be safely carried out in compliance with the UK and Scottish Governments' social distancing measures.
Sistemic are delighted to announce a new article published on RegMedNet titled “In vitro assays for residual pluripotent stem cells in derived cell therapy products: what’s the current state of play?”.
We are taking this opportunity to let you know that as of 20.30 GMT 23rd March 2020 the UK and Scottish Governments issued further legally enforced social distancing measures, and as part of this, have instructed all non-essential businesses to close with immediate effect. They have stated that this situation will be reviewed following an initial 3 week period, in the first instance.
We would like to provide you with an update regarding our plans for dealing with the COVID-19 outbreak, as well as our commitment to working with you on your important projects. We are following UK Public Health Policy and all Government advice to ensure that we fully comply with guidance as it occurs.